• Rapid Dose Therapeutics (CSE:DOSE) and a team from McMaster University have discovered a new way to create THC from CBD
  • Specifically, the process can generate delta 8 or delta 9 types of synthetic THC from hemp-derived CBD
  • Rapid Dose has filed a non-provisional patent for the method with the US Patent and Trademark Office
  • The company considers this a major breakthrough for both the business and the industry as a whole
  • Rapid Dose Therapeutics (DOSE) is up 16.28 per cent and is currently trading at C$0.25 per share

Rapid Dose Therapeutics (CSE:DOSE) and a team from McMaster University have discovered a new way to create THC from CBD.

The process specifically produces delta 8 or delta 9 types of synthetic THC from hemp-derived CBD isolate or distillate. 

Rapid Dose considers the discovery to be a major breakthrough for the business and the cannabis industry as well.

Rapid Dose Therapeutics’ CEO, Mark Upsdell, suggested that the company may combine the innovative technique with its QuickStrip delivery system.

Rapid Dose made the discovery in conjunction with a team led by Dr James McNulty. Dr McNulty, of McMaster University, excitedly commented on the breakthrough, which may lead to many new opportunities in the field.

“This process is novel and highly efficient at selectively converting CBD isolate or distillate into synthetic THC.

“Our collaboration with RDT has resulted in a transformative outcome that we are proud to be involved with. There are numerous high-yield derivatives we can control for using naturally derived CBD through the innovative conversion.

“My team is excited about the possibilities to provide pure cannabinoids for life science companies,” he said.

Rapid Dose has now filed a non-provisional patent for the method with the United States Patent and Trademark Office.

The company’s Senior Vice President, Jason Lewis, indicated that the method will revolutionise worldwide access to delta 8 or delta 9 THC. Particularly, it could relieve dependence on the complicated variables related to indoor and outdoor cannabis cultivation. 

Rapid Dose Therapeutics (DOSE) is up 16.28 per cent and is trading at C$0.25 per share at 10:54am EDT.

More From The Market Online

Telo Genomics and Emery Pharma collaborate

Telo Genomics (TSXV:TELO) collaborates with Emery Pharma to enhance cellular and molecular bioanalytical solutions for clinical research.

UniDoc brings AI to ER patients

UniDoc (CSE:UDOC) expands its AI partnership with DocBox, further integrating predictive analytics into emergency room operations.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.